Trials / Completed
CompletedNCT00911911
Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy
Analysis of the Proteomic Signature in Breast Cancer Correlated With Tumor Response in Patients Necessitating a Neo-adjuvant Chemotherapy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Centre Oscar Lambret · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The scope of the trial is to identify proteomic signatures correlated with tumor response to neo-adjuvant chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood sampling | Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy |
| PROCEDURE | BIOPSY | Biopsy at the moment of inclusion, before neoadjuvant chemotherapy |
| PROCEDURE | SURGERY | Surgery after neoadjuvant chemotherapy |
Timeline
- Start date
- 2007-02-22
- Primary completion
- 2009-01-01
- Completion
- 2012-01-16
- First posted
- 2009-06-03
- Last updated
- 2026-03-13
Locations
5 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00911911. Inclusion in this directory is not an endorsement.